Eli Lilly and Company $LLY Stock Position Lowered by Alecta Tjanstepension Omsesidigt

Key Points

• Alecta Tjanstepension Omsesidigt reduced its Eli Lilly stake by 18.3% in the fourth quarter, selling 99,300 shares and ending with 444,100 shares worth about $477.3 million. Despite the trim, LLY remains its 10th-largest holding.
• Institutional ownership remains very high, with hedge funds and other institutions holding about 82.53% of Eli Lilly’s stock. Several major investors, including Capital Research, Vanguard, Amundi, Jennison, and Victory Capital, increased their positions recently.
• Fundamentals and analyst sentiment remain broadly positive: Lilly beat quarterly earnings and revenue estimates, raised attention around strong GLP-1 drug demand, and announced a $4.5 billion expansion of Indiana manufacturing sites. Analysts’ consensus rating remains “Moderate Buy,” with a consensus price target of $1,218.33.

Alecta Tjanstepension Omsesidigt decreased its position in Eli Lilly and Company (NYSE:LLY - Free Report) by 18.3% in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 444,100 shares of the company's stock after selling 99,300 shares during the quarter. Eli Lilly and Company comprises about 2.1% of Alecta Tjanstepension Omsesidigt's holdings, making the stock its 10th largest position. Alecta Tjanstepension Omsesidigt's holdings in Eli Lilly and Company were worth $477,305,000 at the end of the most recent reporting period.

Several other institutional investors have also recently added to or reduced their stakes in LLY. Capital Research Global Investors raised its stake in Eli Lilly and Company by 20.9% in the 3rd quarter. Capital Research Global Investors now owns 25,088,371 shares of the company's stock valued at $19,141,787,000 after purchasing an additional 4,332,008 shares during the last quarter. Vanguard Group Inc. raised its stake in Eli Lilly and Company by 1.2% in the 4th quarter. Vanguard Group Inc. now owns 81,965,974 shares of the company's stock valued at $88,087,193,000 after purchasing an additional 1,006,885 shares during the last quarter. Amundi raised its stake in Eli Lilly and Company by 27.1% in the 3rd quarter. Amundi now owns 4,525,902 shares of the company's stock valued at $3,823,977,000 after purchasing an additional 964,675 shares during the last quarter. Jennison Associates LLC raised its stake in Eli Lilly and Company by 22.3% in the 4th quarter. Jennison Associates LLC now owns 5,133,676 shares of the company's stock valued at $5,517,059,000 after purchasing an additional 937,204 shares during the last quarter. Finally, Victory Capital Management Inc. raised its stake in Eli Lilly and Company by 47.6% in the 3rd quarter. Victory Capital Management Inc. now owns 2,309,006 shares of the company's stock valued at $1,761,772,000 after purchasing an additional 744,868 shares during the last quarter. Institutional investors and hedge funds own 82.53% of the company's stock.

More Eli Lilly and Company News

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Rothschild & Co Redburn raised its price target on Eli Lilly to $900 from $880, signaling continued confidence in the company’s long-term value despite the target still sitting below the recent share price. MarketScreener
• Positive Sentiment: Multiple reports highlighted strong demand for Lilly’s GLP-1 medicines, including Mounjaro, with first-quarter sales described as a major driver of revenue growth and a key reason investors remain optimistic about future earnings. Motley Fool
• Positive Sentiment: Reuters reported that early weight-loss pill data is boosting Lilly and Novo Nordisk by raising hopes the market could expand beyond injections to millions more patients, which could support a larger long-term revenue opportunity. Reuters
• Positive Sentiment: Lilly announced an additional $4.5 billion investment in Indiana manufacturing sites, reinforcing confidence in its ability to meet future demand for weight-loss and other therapies while expanding U.S. production capacity. Benzinga
• Neutral Sentiment: Several commentary pieces continued to frame Lilly as a high-quality growth stock, but these were largely reiterations of the bullish long-term thesis rather than fresh catalysts. Zacks
• Neutral Sentiment: Articles about shareholder support for the board and broader analyst upgrades suggest stable governance and sentiment, but they do not appear to be major standalone trading catalysts. TipRanks
• Negative Sentiment: One article noted that Eli Lilly’s valuation remains rich and that some investors see more upside in competitors, which can limit enthusiasm even when fundamentals are strong. Motley Fool

Wall Street Analyst Weigh In

LLY has been the subject of several analyst reports. Leerink Partners cut their target price on shares of Eli Lilly and Company from $1,296.00 to $1,058.00 and set an "outperform" rating for the company in a research note on Monday, April 27th. Deutsche Bank Aktiengesellschaft reaffirmed a "buy" rating and set a $1,285.00 price objective on shares of Eli Lilly and Company in a research note on Friday, March 6th. Loop Capital set a $1,200.00 price objective on shares of Eli Lilly and Company in a research note on Tuesday, February 10th. HSBC downgraded shares of Eli Lilly and Company from a "hold" rating to a "reduce" rating and dropped their price objective for the company from $1,070.00 to $850.00 in a research note on Tuesday, March 17th. Finally, TD Cowen upped their price objective on shares of Eli Lilly and Company from $960.00 to $1,250.00 and gave the company a "buy" rating in a research note on Thursday, January 29th. Two research analysts have rated the stock with a Strong Buy rating, twenty-three have given a Buy rating, four have issued a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and a consensus price target of $1,218.33.

Eli Lilly and Company Stock Performance

Eli Lilly and Company stock opened at $948.01 on Friday. The stock has a market cap of $892.78 billion, a P/E ratio of 33.68, a price-to-earnings-growth ratio of 1.07 and a beta of 0.48. The company has a current ratio of 1.50, a quick ratio of 1.10 and a debt-to-equity ratio of 1.26. The stock has a 50 day moving average of $943.90 and a 200-day moving average of $990.90. Eli Lilly and Company has a 52 week low of $623.78 and a 52 week high of $1,133.95.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last released its earnings results on Thursday, April 30th. The company reported $8.55 EPS for the quarter, beating the consensus estimate of $6.97 by $1.58. The company had revenue of $19.80 billion during the quarter, compared to analysts' expectations of $17.82 billion. Eli Lilly and Company had a return on equity of 105.77% and a net margin of 34.98%.The business's revenue was up 55.5% on a year-over-year basis. During the same period in the prior year, the business posted $3.34 EPS. Eli Lilly and Company has set its FY 2026 guidance at 35.500-37.000 EPS. On average, analysts expect that Eli Lilly and Company will post 35.68 EPS for the current fiscal year.

Eli Lilly and Company Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Wednesday, June 10th. Investors of record on Friday, May 15th will be given a dividend of $1.73 per share. This represents a $6.92 annualized dividend and a dividend yield of 0.7%. The ex-dividend date of this dividend is Friday, May 15th. Eli Lilly and Company's dividend payout ratio is currently 24.58%.

Eli Lilly and Company Company Profile

Eli Lilly and Company NYSE: LLY is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.